HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Histone Deacetylase Inhibitors

Subscribe to New Research on Histone Deacetylase Inhibitors

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.

Also Known As:

HDAC Inhibitors; Histone Deacetylase Inhibitor; Deacetylase Inhibitor, Histone; Deacetylase Inhibitors, Histone; Inhibitor, Histone Deacetylase; Inhibitors, HDAC; Inhibitors, Histone Deacetylase

Networked: 3210 relevant articles (223 outcomes, 577 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 56
  - Molecular Mechanisms of Pharmacological Action: 7
    - Enzyme Inhibitors: 685
      - Histone Deacetylase Inhibitors: 3210

Experts

1.	Grant, Steven: 47 articles (10/2014 - 02/2002)
2.	Atadja, Peter: 43 articles (01/2015 - 08/2003)
3.	Dent, Paul: 32 articles (05/2014 - 05/2003)
4.	Marks, Paul A: 30 articles (04/2012 - 05/2002)
5.	Alam, Hasan B: 28 articles (01/2016 - 03/2006)
6.	Johnstone, Ricky W: 26 articles (01/2015 - 04/2002)
7.	Richon, Victoria M: 25 articles (07/2015 - 03/2002)
8.	Liu, Baoling: 24 articles (06/2015 - 06/2007)
9.	Chen, Ching-Shih: 23 articles (12/2015 - 10/2004)
10.	Li, Yongqing: 22 articles (06/2015 - 06/2007)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2011 - "Numerous studies have identified that histone deacetylase inhibitors will be most effective in the clinic when used in combination with conventional cancer therapies such as ionizing radiation and chemotherapeutic agents. " 09/01/2010 - "A large number of HDAC inhibitors have been synthesized in the last few years, most being effective in vitro, inducing cancer cells differentiation or cell death. " 07/01/2015 - "Several studies have addressed the identification of putative HDAC inhibitors as therapeutic agents for cancer and until now those cleared phase III human trials are very limited. " 07/01/2002 - "Further studies are needed in order to delineate the optimal dosage, the duration of therapy and possibly the efficacy of other agents able to synergize with HDAC inhibitors in the fight against cancer." 10/01/2013 - "Histone deacetylase inhibitors (HDACi) are a promising class of anti-cancer drugs but their single agent efficacy against relapsed DLBCL has been variable, ranging from few complete/partial responses to some stable disease. "
2.	Leukemia 07/01/2011 - "MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)." 01/01/2000 - "Interestingly, another group has recently reported that phenylbutyrate, which is also known as a histone deacetylase inhibitor, is very effective for leukemia patients. " 01/01/2006 - "They also raise the possibility that a strategy combining CDK and HDAC inhibitors may be effective against drug-resistant leukemia cells overexpressing Bcl-2 or Bcl-x(L)." 04/01/2014 - "Altogether, our study identifies histone deacetylase inhibitors as potential candidates for the treatment of certain leukemias characterized by down-regulation of the C/EBPα signature. " 04/01/2012 - "Given the presented potential of HDAC inhibitors to target important proto-oncogenes including the leukemia-specific MLL fusion in vitro, these agents should urgently be tested in in vivo models and subsequent clinical trials."
3.	Neurodegenerative Diseases (Neurodegenerative Disease) 11/01/2009 - "We discuss the targets and mechanisms underlying these effects of HDAC inhibition and comment on the potential for some HDAC inhibitors to prove clinically effective in the treatment of neurodegenerative disorders." 11/01/2009 - "We summarize the results from these studies, which indicate that HDAC inhibitors show great promise as therapeutic agents for human neurodegenerative disorders." 12/01/2008 - "This study indicates that astrocytes may be a critical neuroprotective mechanism of HDAC inhibitors, revealing a novel target for the treatment of psychiatric and neurodegenerative diseases." 10/01/2014 - "Moreover, recent findings have suggested an important role for HDAC inhibitors in enhancing learning and memory processes as well as ameliorating symptoms related to neurodegenerative diseases. " 01/01/2014 - "Although histone deacetylase inhibitors are currently used as therapeutic agents, we raise the untapped potential of the nucleolar transcription of ribosomal genes as an exciting new target for the therapy of some neurodegenerative diseases. "
4.	Breast Neoplasms (Breast Cancer) 04/01/2012 - "Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells." 01/01/2014 - "These studies demonstrate that select HDAC inhibitors increase oHSV replication in breast cancer cells and provides support for pre-clinical evaluation of this combination strategy. " 10/20/2015 - "Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells." 08/01/2015 - "Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression." 04/01/2015 - "HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cells."
5.	Colorectal Neoplasms (Colorectal Cancer) 02/01/2009 - "Our findings firstly demonstrated the chemo-responsiveness of colorectal cancers to HDAC inhibitors with therapeutic efficacy comparable to the established regimens. " 07/15/2015 - "Thus, combinations of MEKi with inhibitors of c-MET or c-FLIP (e.g., HDAC inhibitors) could be potential novel treatment strategies for BRAFMT colorectal cancer." 11/02/2015 - "Histone deacetylase inhibitors (HDACIs) have been shown to have antiproliferative activity through cell-cycle arrest, differentiation, and apoptosis in colorectal cancer (CRC) cells. " 04/01/2015 - "A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells." 10/01/2014 - "Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells."

Related Drugs and Biologics

1.	Histone Deacetylases (Histone Deacetylase)
2.	vorinostat (suberoylanilide hydroxamic acid)
3.	Valproic Acid (Valproate, Semisodium)
4.	DNA (Deoxyribonucleic Acid)
5.	LBH589
6.	trichostatin A (A 300)
7.	Butyrates (Butyrate)
8.	romidepsin (FK228)
9.	Proteasome Endopeptidase Complex (Proteasome)
10.	Histones (Histone)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Heterologous Transplantation (Xenotransplantation)
4.	Radiotherapy
5.	Molecular Targeted Therapy